OGN · Organon & Co. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | - | $1.60B | $1.59B | $1.51B | - | $1.58B | $1.61B | $1.62B | - |
| Cost of Revenue | $677.00M | - | $745.00M | $720.00M | $672.00M | - | $659.00M | $668.00M | $665.00M | - |
| Gross Profit | $783.00M | - | $857.00M | $874.00M | $957.00M | - | $923.00M | $968.00M | $957.00M | - |
| R&D | $93.00M | - | $84.00M | $95.00M | $96.00M | - | $111.00M | $116.00M | $112.00M | - |
| SG&A | $424.00M | - | $415.00M | $453.00M | $420.00M | - | $422.00M | $437.00M | $431.00M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $39.00M | - | - | - | $34.00M | - | - | - | $32.00M | - |
| Operating Income | $213.00M | - | $243.00M | $229.00M | $101.00M | - | $207.00M | $235.00M | $236.00M | - |
| Interest Expense | $111.00M | - | $128.00M | $131.00M | $124.00M | - | $126.00M | $131.00M | $131.00M | - |
| Income Tax | $67.00M | - | $83.00M | $84.00M | $14.00M | - | ($152.00M) | $40.00M | $35.00M | - |
| Net Income | $146.00M | - | $160.00M | $145.00M | $87.00M | - | $359.00M | $195.00M | $201.00M | - |
| EPS - Basic | $0.56 | - | $0.61 | $0.56 | $0.34 | - | $1.39 | $0.76 | $0.78 | - |
| EPS - Diluted | $0.55 | - | $0.61 | $0.56 | $0.33 | - | $1.38 | $0.75 | $0.78 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.12B | $574.00M | $672.00M | $599.00M | $547.00M | $675.00M | $763.00M | $704.00M | $575.00M | $693.00M |
| Accounts Receivable | $1.38B | $1.33B | $1.48B | $1.48B | $1.46B | $1.36B | $1.69B | $1.62B | $1.55B | $1.74B |
| Inventory | $1.37B | $1.41B | $1.49B | $1.45B | $1.36B | $1.32B | $1.38B | $1.29B | $1.26B | $1.31B |
| Accounts Payable | $983.00M | $952.00M | $1.07B | $1.07B | $1.01B | $1.15B | $1.09B | $1.24B | $955.00M | $1.31B |
| Current Assets | $4.93B | $4.35B | $4.70B | $4.62B | $4.37B | $4.35B | $4.76B | $4.51B | $4.20B | $4.51B |
| Total Assets | $13.00B | $12.87B | $13.55B | $13.50B | $13.16B | $13.10B | $12.75B | $12.15B | $11.89B | $12.06B |
| Current Liabilities | $2.50B | $2.39B | $2.68B | $2.80B | $2.62B | $2.72B | $2.79B | $2.75B | $2.54B | $2.92B |
| Long-term Debt | $8.55B | $8.63B | $8.78B | $8.78B | $8.94B | $8.86B | $8.74B | $8.65B | $8.71B | $8.75B |
| Total Liabilities | $12.09B | $12.12B | $12.65B | $12.77B | $12.61B | $12.63B | $12.26B | $12.01B | $11.84B | $12.13B |
| Stockholders' Equity | $903.00M | $752.00M | $906.00M | $733.00M | $542.00M | $472.00M | $493.00M | $144.00M | $48.00M | ($70.00M) |
| Retained Earnings | $1.25B | $1.11B | $1.32B | $1.16B | $1.03B | $1.01B | $975.00M | $690.00M | $573.00M | $443.00M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $225.00M | - | - | - | $75.00M | - | - | - | $76.00M | - |
| Investing Cash Flow | $386.00M | - | - | - | ($172.00M) | - | - | - | ($96.00M) | - |
| Financing Cash Flow | ($38.00M) | - | - | - | ($75.00M) | - | - | - | ($74.00M) | - |
| CapEx | $37.00M | - | - | - | $32.00M | - | - | - | $46.00M | - |
| Free Cash Flow | $188.00M | - | - | - | $43.00M | - | - | - | $30.00M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 53.6% | - | 53.5% | 54.8% | 63.3% | - | 58.3% | 60.2% | 59.0% | - |
| Operating margin | 14.6% | - | 15.2% | 14.4% | 6.7% | - | 13.1% | 14.6% | 14.5% | - |
| EBITDA margin | 17.3% | - | - | - | 8.9% | - | - | - | 16.5% | - |
| Net margin | 10.0% | - | 10.0% | 9.1% | 5.8% | - | 22.7% | 12.1% | 12.4% | - |
| Free cash flow margin | 12.9% | - | - | - | 2.8% | - | - | - | 1.8% | - |
| FCF / Net income | 1.29 | - | - | - | 0.49 | - | - | - | 0.15 | - |
| R&D / Revenue | 6.4% | - | 5.2% | 6.0% | 6.3% | - | 7.0% | 7.2% | 6.9% | - |
| SG&A / Revenue | 29.0% | - | 25.9% | 28.4% | 27.8% | - | 26.7% | 27.2% | 26.6% | - |
| Effective tax rate | 31.5% | - | 34.2% | 36.7% | 13.9% | - | -73.4% | 17.0% | 14.8% | - |
| Return on assets | 1.1% | - | 1.2% | 1.1% | 0.7% | - | 2.8% | 1.6% | 1.7% | - |
| Return on equity | 16.2% | - | 17.7% | 19.8% | 16.1% | - | 72.8% | 135.4% | 418.8% | - |
| Return on invested capital | 1.5% | - | 1.7% | 1.5% | 0.9% | - | 2.2% | 2.2% | 2.3% | - |
| Liquidity | ||||||||||
| Current ratio | 1.97 | 1.82 | 1.75 | 1.65 | 1.67 | 1.60 | 1.70 | 1.64 | 1.65 | 1.54 |
| Quick ratio | 1.42 | 1.23 | 1.20 | 1.13 | 1.15 | 1.11 | 1.21 | 1.17 | 1.15 | 1.09 |
| Cash ratio | 0.45 | 0.24 | 0.25 | 0.21 | 0.21 | 0.25 | 0.27 | 0.26 | 0.23 | 0.24 |
| Leverage | ||||||||||
| Debt / Equity | 9.47 | 11.47 | 9.69 | 11.98 | 16.49 | 18.77 | 17.73 | 60.05 | 181.35 | -125.01 |
| Debt / Assets | 0.66 | 0.67 | 0.65 | 0.65 | 0.68 | 0.68 | 0.69 | 0.71 | 0.73 | 0.73 |
| Debt / EBITDA | 33.94 | - | - | - | 66.19 | - | - | - | 32.48 | - |
| Interest coverage | 1.9x | - | 1.9x | 1.7x | 0.8x | - | 1.6x | 1.8x | 1.8x | - |
| Equity multiplier | 14.39 | 17.11 | 14.96 | 18.42 | 24.27 | 27.76 | 25.87 | 84.40 | 247.73 | -172.26 |
| Liabilities / Assets | 0.93 | 0.94 | 0.93 | 0.95 | 0.96 | 0.96 | 0.96 | 0.99 | 1.00 | 1.01 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.12 | 0.12 | 0.12 | - | 0.12 | 0.13 | 0.14 | - |
| Inventory turnover | 0.49 | - | 0.50 | 0.50 | 0.49 | - | 0.48 | 0.52 | 0.53 | - |
| Days sales outstanding | 346d | - | 338d | 340d | 351d | - | 389d | 367d | 348d | - |
| Days inventory outstanding | 740d | - | 729d | 737d | 740d | - | 766d | 703d | 693d | - |
| Days payable outstanding | 530d | - | 526d | 541d | 546d | - | 605d | 679d | 524d | - |
| Cash conversion cycle | 556d | - | 541d | 536d | 545d | - | 550d | 391d | 517d | - |
| Valuation | ||||||||||
| P / E | 10.9x | - | 17.5x | 17.3x | 45.1x | - | 13.9x | 27.6x | 24.1x | - |
| P / B | 1.7x | - | 3.1x | 3.4x | 7.2x | - | 10.1x | 37.2x | 101.2x | - |
| P / S | 1.1x | - | 1.7x | 1.6x | 2.6x | - | 3.1x | 3.3x | 3.0x | - |
| EV / EBITDA | 35.8x | - | - | - | 90.9x | - | - | - | 48.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -3.5% | - | 1.3% | -0.8% | -6.7% | - | 4.1% | -0.1% | 5.5% | - |
| Revenue CAGR (3y) | -1.7% | - | 1.4% | 0.2% | -1.2% | - | -0.4% | 1.7% | -3.1% | - |
| Revenue CAGR (5y) | -3.9% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -18.2% | - | -7.2% | -9.7% | 0.0% | - | 1.8% | 0.0% | -0.1% | - |
| Operating income growth (YoY) | 110.9% | - | 17.4% | -2.6% | -57.2% | - | 158.8% | -7.5% | 0.4% | - |
| Net income growth (YoY) | 67.8% | - | -55.4% | -25.6% | -56.7% | - | 519.0% | -19.4% | 13.6% | - |
| EPS growth (YoY) | 66.7% | - | -55.8% | -25.3% | -57.7% | - | 500.0% | -21.1% | 13.0% | - |
| EPS CAGR (3y) | -7.3% | - | -11.8% | -15.3% | -37.6% | - | -13.9% | -29.5% | -34.5% | - |
| EPS CAGR (5y) | -27.7% | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 337.2% | - | - | - | 43.3% | - | - | - | -61.0% | - |
| FCF CAGR (5y) | -23.3% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 66.6% | 59.3% | 83.8% | 409.0% | 1029.2% | - | - | - | - | 92.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$3.01B totalNexplanon Implanon NXT$610.00M · 20.3%
Atozet$324.00M · 10.8%
Arcoxia$265.00M · 8.8%
Nasonex$261.00M · 8.7%
Renflexis$183.00M · 6.1%
Emgality Ravvow$174.00M · 5.8%
Hadlima$166.00M · 5.5%
Diprospan$150.00M · 5.0%
Marvelon Mercilon$127.00M · 4.2%
Dulera$113.00M · 3.8%
Follistim AQ$112.00M · 3.7%
Vtama$111.00M · 3.7%
Brenzys$80.00M · 2.7%
Jada$73.00M · 2.4%
Other Womens Health$65.00M · 2.2%
Other Respiratory$42.00M · 1.4%
Rosuzet$24.00M · 0.8%
Nuva Ring$19.00M · 0.6%
Other Biosimilars$17.00M · 0.6%
Other Non Opiod Pain Bone And Dermatology$16.00M · 0.5%
Ontruzant$15.00M · 0.5%
Ganirelix Acetate Injection$12.00M · 0.4%
Other Sundry Established Brands$10.00M · 0.3%
Cozaar Hyzaar$8.00M · 0.3%
Singulair$8.00M · 0.3%
Propecia$6.00M · 0.2%
Zetia$5.00M · 0.2%
Vytorin$4.00M · 0.1%
Other Cardiovascular$3.00M · 0.1%
Clarinex$2.00M · 0.1%
Fosamax$2.00M · 0.1%
Other Sundry Products$1.00M · 0.0%
Proscar$1.00M · 0.0%
Geographic
$10.83B totalNon Us$4.61B · 42.6%
Europe And Canada$1.62B · 14.9%
US$1.60B · 14.8%
Latin America Middle East Russia And Africa$1.07B · 9.9%
Asia Pacific And Japan$1.00B · 9.2%
CN$829.00M · 7.7%
Other Countries$93.00M · 0.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Organon & Co. against the 5 most active filers in the same SIC group.
Dividends
$0.08/share trailing 12 months · -90.7% YoY
| Ex-date | Per share |
|---|---|
| May 11, 2026 | $0.0200 |
| Feb 23, 2026 | $0.0200 |
| Nov 20, 2025 | $0.0200 |
| Aug 15, 2025 | $0.0200 |
| May 12, 2025 | $0.0200 |
| Feb 24, 2025 | $0.2800 |
| Nov 12, 2024 | $0.2800 |
| Aug 16, 2024 | $0.2800 |
| May 10, 2024 | $0.2800 |
| Feb 23, 2024 | $0.2800 |
| Nov 10, 2023 | $0.2800 |
| Aug 17, 2023 | $0.2800 |
| May 12, 2023 | $0.2800 |
| Feb 24, 2023 | $0.2800 |
| Nov 10, 2022 | $0.2800 |
| Aug 12, 2022 | $0.2800 |
| May 13, 2022 | $0.2800 |
| Feb 25, 2022 | $0.2800 |
| Nov 19, 2021 | $0.2800 |
| Aug 20, 2021 | $0.2800 |